Systemic amyloidosis: moving into the spotlight
OC Cohen, AD Wechalekar - Leukemia, 2020 - nature.com
Systemic amyloidosis is a rare but increasingly recognised disease that is heterogeneous in
presentation. Early diagnosis, whilst imperative, remains challenging but can improve …
presentation. Early diagnosis, whilst imperative, remains challenging but can improve …
Updates in the diagnosis and management of AL amyloidosis
Abstract Purpose of Review Light chain (AL) amyloidosis is an insidious progressive
disease which results in significant morbidity and inevitable mortality if not diagnosed and …
disease which results in significant morbidity and inevitable mortality if not diagnosed and …
Impact of minimal residual negativity using next generation flow cytometry on outcomes in light chain amyloidosis
We evaluated bone marrow minimal residual disease (MRD) negativity in 44 patients with
light chain (AL) amyloidosis using next generation flow cytometry (sensitivity≥ 1× 10− 5; …
light chain (AL) amyloidosis using next generation flow cytometry (sensitivity≥ 1× 10− 5; …
Optimizing deep response assessment for AL amyloidosis using involved free light chain level at end of therapy: failure of the serum free light chain ratio
The baseline level of involved free light chains (iFLC) is prognostic in light chain (AL)
amyloidosis [1, 2]. A reduction in iFLC is associated with improved survival and organ …
amyloidosis [1, 2]. A reduction in iFLC is associated with improved survival and organ …
Blood mass spectrometry detects residual disease better than standard techniques in light-chain amyloidosis
A Dispenzieri, B Arendt, S Dasari, M Kohlhagen… - Blood cancer …, 2020 - nature.com
In patients with immunoglobulin light-chain (AL) amyloidosis, depth of hematologic response
correlates with both organ response and overall survival. Our group has demonstrated that …
correlates with both organ response and overall survival. Our group has demonstrated that …
Refining amyloid complete hematological response: Quantitative serum free light chains superior to ratio
Response assessment in light chain (AL) amyloidosis is based on serum and urine
monoclonal protein studies. Newly diagnosed patients (n= 373) who achieved very good …
monoclonal protein studies. Newly diagnosed patients (n= 373) who achieved very good …
Survival impact of achieving minimal residual negativity by multi-parametric flow cytometry in AL amyloidosis
Response assessment in light chain (AL) amyloidosis is challenging given the low level of
circulating free light chains usually seen. Multi-parametric flow cytometry (MFC) from a …
circulating free light chains usually seen. Multi-parametric flow cytometry (MFC) from a …
When should treatment of AL amyloidosis start at relapse? Early, to prevent organ progression
G Palladini, G Merlini - Blood Advances, 2019 - ashpublications.org
When should treatment of AL amyloidosis start at relapse? Early, to prevent organ progression
| Blood Advances | American Society of Hematology Skip to Main Content Advertisement …
| Blood Advances | American Society of Hematology Skip to Main Content Advertisement …
Revisiting complete response in light chain amyloidosis
Organ dysfunction in light chain amyloidosis (AL) results from deposition of misfolded
monoclonal free light chains (FLC). A rapid reduction in FLC levels correlates with …
monoclonal free light chains (FLC). A rapid reduction in FLC levels correlates with …
[HTML][HTML] Prognostic significance of stringent complete response after stem cell transplantation in immunoglobulin light chain amyloidosis
Hematologic response has emerged as a powerful prognostic factor for survival in patients
with immunoglobulin light chain (AL) amyloidosis. Patients achieving a complete response …
with immunoglobulin light chain (AL) amyloidosis. Patients achieving a complete response …